Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).

Abrisqueta P, González-Barca E, Ferrà C, Ríos-Herranz E, Fernández de la Mata M, Delgado J, Andreu R, Hernández-Rivas JÁ, Terol MJ, Navarro A, Vidriales MB, Baltasar P, De la Serna J, Ramírez Á, Ballester C, Moreno C, García-Marco JA, Córdoba R, Yáñez L, Casado LF, González M, Bosch F

Open source

DOI: 10.1016/j.eclinm.2024.102642
Published: 2024 Jul
Container: EClinicalMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2024.102642,
  title = {Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).},
  author = {Abrisqueta P and González-Barca E and Ferrà C and Ríos-Herranz E and Fernández de la Mata M and Delgado J and Andreu R and Hernández-Rivas JÁ and Terol MJ and Navarro A and Vidriales MB and Baltasar P and De la Serna J and Ramírez Á and Ballester C and Moreno C and García-Marco JA and Córdoba R and Yáñez L and Casado LF and González M and Bosch F},
  year = {2024},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2024.102642},
  url = {https://doi.org/10.1016/j.eclinm.2024.102642}
}

RIS

TY  - JOUR
TI  - Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
AU  - Abrisqueta P
AU  - González-Barca E
AU  - Ferrà C
AU  - Ríos-Herranz E
AU  - Fernández de la Mata M
AU  - Delgado J
AU  - Andreu R
AU  - Hernández-Rivas JÁ
AU  - Terol MJ
AU  - Navarro A
AU  - Vidriales MB
AU  - Baltasar P
AU  - De la Serna J
AU  - Ramírez Á
AU  - Ballester C
AU  - Moreno C
AU  - García-Marco JA
AU  - Córdoba R
AU  - Yáñez L
AU  - Casado LF
AU  - González M
AU  - Bosch F
PY  - 2024
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2024.102642
UR  - https://doi.org/10.1016/j.eclinm.2024.102642
ER  -

APA

P, A., E, G., C, F., E, R., M, F. D. L. M., J, D., R, A., JÁ, H., MJ, T., A, N., MB, V., P, B., J, D. L. S., Á, R., C, B., C, M., JA, G., R, C., L, Y., LF, C., M, G., & F, B. (2024). Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2024.102642

Source records

pubmed · retrieved 2026-09-25T17:27:02.834Z